English, Article edition: Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK Mark Nuijten; Liebeth Meester; Franz Waibel; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94804
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
Author
  • Mark Nuijten
  • Liebeth Meester
  • Franz Waibel
  • Suzanne Wait
Physical Description
  • article
Notes
  • Objective: To simulate the treatment of postmenopausal women with advanced breast cancer from second-line hormone therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the incremental cost effectiveness of letrozole, expressed as cost per life-years gained. Design: A decision-analytic model, using Markov process techniques, was designed to evaluate the lifetime clinical and economic consequences of treatment with letrozole compared with standard care with megestrol. The model was based on clinical trial results showing a clear advantage of letrozole in terms of time to progression and duration of response. Setting: The setting of the study was that of the UK healthcare system in 1996. Patients and participants: A hypothetical cohort of patients, identical to the patients recruited for the AR/​BC2 clinical trial, who were postmenopausal women with advanced breast cancer who had previously failed to respond to first-line or adjuvant anti-estrogen therapy. Interventions: The dosages of medications were 2.5 and 160 mg/​day for letrozole and megestrol, respectively. The analysis covered the period from treatment initiation until death (lifetime model). Effectiveness was expressed as survival and time without progression, and the model also included all relevant economic measures. Main outcome measures and results: Based on the model, the average survival time of the letrozole group was 2.1 years (25.3 months) versus 1.9 years (21.5 months) for the megestrol group, a gain in survival of 2.4 months (10.5%). The average time without progression, cumulatively calculated over the different treatment options, amounted to 20.2 months for letrozole and 17.8 months for megestrol, an increase of 13.7% for the former patients. The total average cost per patient for the treatment of advanced breast cancer starting from second-line hormone therapy until death was higher in the letrozole group at Lstg 7547 versus Lstg 6820 for the megestrol group (discounted at an annual rate of 5%), leading to an incremental cost-effectiveness ratio of Lstg 3588 per life-year gained (1996 values). Conclusions: Based on the assumptions used in this model, letrozole offers a suitable alternative to megestrol in the treatment of second-line hormone therapy.
  • Pharmacoeconomics, Letrozole, Breast-cancer, Megestrol, Cost-effectiveness, Menopause, Mortality, Hormones
  • RePEc:wkh:phecon:v:16:y:1999:i:4:p:379-397
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment